Amphastar Pharmaceuticals, Inc. (AMPH)

Market Cap	936.13M -26.2%
Revenue (ttm)	719.89M -1.7%
Net Income	98.09M -38.5%
EPS	2.03 -33.7%
Shares Out	44.53M
PE Ratio	10.30
Forward PE	6.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,370
Open	20.99
Previous Close	20.99
Day's Range	20.84 - 21.23
52-Week Range	17.03 - 31.26
Beta	0.91
Analysts	Buy
Price Target	28.38 (+35.01%)
Earnings Date	May 7, 2026

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the preven...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2014
• Employees: 1,976
• Stock Exchange: NASDAQ
• Ticker Symbol: AMPH
• Website: https://www.amphastar.com

Financial Performance

In 2025, Amphastar Pharmaceuticals's revenue was $719.89 million, a decrease of -1.65% compared to the previous year's $731.97 million. Earnings were $98.09 million, a decrease of -38.51%.

Analyst Summary

According to 8 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price target is $28.38, which is an increase of 35.01% from the latest price.

Price Target

$28.38

(35.01% upside)

Analyst Consensus: Buy